HF
ABOS icon

HRT Financial’s Acumen Pharmaceuticals ABOS Stock Holding History

HRT Financial’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31K Buy
+13,162
New +$33.6K ﹤0.01% 3522
2025
Q4 		– Sell
-14,014
Closed -$23K – 3096
2025
Q3 		$23K Sell
14,014
-17,413
-55% -$24.1K ﹤0.01% 2689
2025
Q2 		$36K Buy
+31,427
New +$33.8K ﹤0.01% 2345
2024
Q2 		– Sell
-105,117
Closed -$425K – 2129
2024
Q1 		$425K Buy
+105,117
New +$396K ﹤0.01% 1343
2023
Q2 		– Sell
-43,115
Closed -$175K – 2359
2023
Q1 		$175K Buy
43,115
+22,443
+109% +$117K ﹤0.01% 1951
2022
Q4 		$111K Buy
+20,672
New +$139K ﹤0.01% 2047
2022
Q1 		– Sell
-81,917
Closed -$553K – 3000
2021
Q4 		$553K Buy
+81,917
New +$900K ﹤0.01% 1672

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

HRT Financial's ABOS Position: Q1 2026 in Review

HRT Financial opened a new position in Acumen Pharmaceuticals (ABOS) in Q1 2026: 13,162 shares worth $31K. The stake represents ﹤0.01% of the portfolio and ranks #3522 among its holdings. This is a return to the name: HRT Financial previously reported a position in ABOS as recently as Q3 2025.

HRT Financial first reported a position in ABOS in Q4 2021 and has held it in 7 quarters since. The position peaked at $553K in Q4 2021. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • HRT Financial held 13,162 shares of Acumen Pharmaceuticals worth $31K as of Q1 2026.
  • Acumen Pharmaceuticals was a new HRT Financial position in Q1 2026.
  • Acumen Pharmaceuticals made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3522 holding.
  • HRT Financial first reported a position in Acumen Pharmaceuticals in Q4 2021 and has held it in 7 quarters since.
  • HRT Financial's Acumen Pharmaceuticals position peaked at $553K in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.